{"id":"v260","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:03:49.976600","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, V260 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"V260 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:52.828Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT01871038","phase":"","title":"Effectiveness of Monovalent Rotavirus Vaccine (RV1)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2009-07","conditions":"Rotavirus, Acute Gastroenteritis","enrollment":362},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT03313128","phase":"","title":"SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-10-05","conditions":"Rotavirus Infections, Environmental Enteric Dysfunction, Enteric Infections","enrollment":261},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06200844","phase":"PHASE3","title":"The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2023-07-07","conditions":"Rotavirus Infection of Children","enrollment":5800},{"nctId":"NCT04658914","phase":"PHASE2","title":"Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2021-04-15","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":720},{"nctId":"NCT01375647","phase":"PHASE3","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2011-05","conditions":"Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy","enrollment":700},{"nctId":"NCT06882070","phase":"","title":"ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-05-04","conditions":"Rotavirus Gastroenteritis, Rotavirus Vaccines, Antimicrobial Resistance (AMR)","enrollment":1600},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT05621655","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2023-01-08","conditions":"Rotavirus Infections, Rotavirus Gastroenteritis","enrollment":1512},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06350058","phase":"PHASE1","title":"Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-08-03","conditions":"Healthy Volunteers","enrollment":375},{"nctId":"NCT02941107","phase":"PHASE4","title":"Optimising Rotavirus Vaccine in Aboriginal Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telethon Kids Institute","startDate":"2018-03-27","conditions":"Viral Gastroenteritis Due to Rotavirus","enrollment":1000},{"nctId":"NCT06080906","phase":"PHASE2","title":"Phase II Clinical Trial of the Inactivated Rotavirus Vaccine","status":"UNKNOWN","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-10-20","conditions":"Rotavirus Infections, Diarrhea","enrollment":600},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04185545","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-10-30","conditions":"Rotavirus Gastroenteritis","enrollment":1400},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT02145000","phase":"PHASE3","title":"Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger","status":"COMPLETED","sponsor":"Epicentre","startDate":"2014-06","conditions":"Severe Rotavirus Gastroenteritis","enrollment":6586},{"nctId":"NCT05958771","phase":"PHASE3","title":"The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2023-07-06","conditions":"Rotavirus Gastroenteritis","enrollment":5800},{"nctId":"NCT03483116","phase":"PHASE2","title":"A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2018-06-15","conditions":"Rotavirus Infections","enrollment":711},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT04344054","phase":"PHASE2","title":"Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2021-02-22","conditions":"Rotavirus Vaccine","enrollment":850},{"nctId":"NCT03587389","phase":"PHASE4","title":"Response to Rotavirus Vaccine in Infants in Ho Chi Minh City in Vietnam","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2019-03-19","conditions":"Rotavirus, Diarrhea","enrollment":818},{"nctId":"NCT02902445","phase":"","title":"Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2017-02-28","conditions":"Gastroenteritis, Acute Gastroenteritis","enrollment":611},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05212935","phase":"","title":"A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2022-05","conditions":"Vaccination, Rotavirus Infections, Meningococcal Infections","enrollment":2000},{"nctId":"NCT03954743","phase":"PHASE3","title":"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-19","conditions":"Infections, Rotavirus","enrollment":1351},{"nctId":"NCT00880698","phase":"PHASE2","title":"Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infection, Rotavirus Infection","enrollment":202},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT05037435","phase":"PHASE3","title":"Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2018-06-25","conditions":"Rotavirus Infections, Rotavirus Vaccines","enrollment":40},{"nctId":"NCT05032391","phase":"PHASE3","title":"Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2019-02-22","conditions":"Rotavirus Infection","enrollment":100},{"nctId":"NCT00439660","phase":"PHASE1, PHASE2","title":"Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2006-12","conditions":"Diarrhea","enrollment":540},{"nctId":"NCT03703336","phase":"PHASE3","title":"Phase III Study of Liquid Formulation of ROTAVIN","status":"COMPLETED","sponsor":"Center for Research and Production of Vaccines and Biologicals, Vietnam","startDate":"2019-03-16","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":825},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT03602053","phase":"PHASE2, PHASE3","title":"Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-01-22","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":450},{"nctId":"NCT04626856","phase":"PHASE1","title":"Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-03","conditions":"Rotavirus Infection","enrollment":32},{"nctId":"NCT02141204","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-02-20","conditions":"Rotavirus","enrollment":451},{"nctId":"NCT04596696","phase":"PHASE3","title":"Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2017-12-20","conditions":"Rotavirus Gastroenteritis","enrollment":360},{"nctId":"NCT02992197","phase":"PHASE4","title":"The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2017-06-12","conditions":"Rotavirus Infection, Vaccine Response Impaired, Vaccine Virus Shedding","enrollment":220},{"nctId":"NCT02646891","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02-15","conditions":"Healthy","enrollment":618},{"nctId":"NCT00750893","phase":"","title":"Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-02","conditions":"Infections, Rotavirus","enrollment":3111},{"nctId":"NCT00385320","phase":"PHASE2","title":"Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-05-31","conditions":"Infections, Rotavirus","enrollment":2640},{"nctId":"NCT04123119","phase":"NA","title":"Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2019-01-22","conditions":"Diarrhoeal Disease","enrollment":22},{"nctId":"NCT03507738","phase":"PHASE1","title":"Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-07-03","conditions":"Healthy","enrollment":110},{"nctId":"NCT03462108","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2018-04-09","conditions":"Safety Issues","enrollment":100},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT03367559","phase":"PHASE3","title":"Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam","status":"UNKNOWN","sponsor":"Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products","startDate":"2018-02-08","conditions":"Rotavirus Infections","enrollment":360},{"nctId":"NCT01700621","phase":"PHASE4","title":"Coadministration of Measles-rubella and Rotavirus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2013-01","conditions":"Measles Antibody Seroconversion, Rubella Antibody Seroconversion, Rotavirus Geometric Mean Titer (GMT)","enrollment":482},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":"Rotavirus Infection","enrollment":48},{"nctId":"NCT00875641","phase":"","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Infections, Rotavirus","enrollment":390659},{"nctId":"NCT03804489","phase":"NA","title":"Using \"Decision Aids\" to Help the Infant Family to Decide the Use of Oral Rotavirus Vaccine","status":"UNKNOWN","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2019-01-25","conditions":"Rotavirus Vaccines","enrollment":180},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT01616693","phase":"PHASE4","title":"Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2012-07","conditions":"Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine","enrollment":620},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT01600092","phase":"PHASE3","title":"A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-29","conditions":"Rotavirus Gastroenteritis","enrollment":1020},{"nctId":"NCT02584816","phase":"PHASE3","title":"Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2015-11","conditions":"Rotavirus Gastroenteritis","enrollment":1500},{"nctId":"NCT02133690","phase":"PHASE3","title":"A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2014-05","conditions":"Rotavirus Gastroenteritis","enrollment":7500},{"nctId":"NCT03474055","phase":"PHASE2, PHASE3","title":"Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-10-30","conditions":"Rotavirus Gastroenteritis","enrollment":1500},{"nctId":"NCT00779779","phase":"","title":"Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-22","conditions":"Infections, Rotavirus","enrollment":522},{"nctId":"NCT00420316","phase":"PHASE3","title":"Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-12","conditions":"Infections, Rotavirus","enrollment":1613},{"nctId":"NCT01886833","phase":"","title":"Causes of Rotavirus Vaccine Failure in Zambian Children","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2012-04-01","conditions":"Diarrhoea","enrollment":420},{"nctId":"NCT01198769","phase":"PHASE4","title":"Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-11","conditions":"Infections, Rotavirus","enrollment":15},{"nctId":"NCT01171963","phase":"PHASE3","title":"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-29","conditions":"Infections, Rotavirus","enrollment":3340},{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144},{"nctId":"NCT02542462","phase":"PHASE4","title":"Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-11","conditions":"Intussusception, Rotavirus Infections","enrollment":144},{"nctId":"NCT00443846","phase":"PHASE3","title":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-13","conditions":"Meningitis, Meningococcal, Rotavirus Infections","enrollment":247},{"nctId":"NCT00420745","phase":"PHASE3","title":"To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-25","conditions":"Infections, Rotavirus","enrollment":1009},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT00938327","phase":"","title":"Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-03","conditions":"Infections, Rotavirus","enrollment":332},{"nctId":"NCT02109484","phase":"PHASE1, PHASE2","title":"Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2014-03","conditions":"Evaluation of a Rotavirus Vaccine","enrollment":204},{"nctId":"NCT01571505","phase":"PHASE1","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2012-03-01","conditions":"Poliomyelitis, Tropical Enteropathy","enrollment":372},{"nctId":"NCT02728869","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants","status":"COMPLETED","sponsor":"MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.","startDate":"2016-06","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT02538211","phase":"NA","title":"The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-09","conditions":"Rotavirus Infections, Intestinal Bacteria Flora Disturbance, Reaction - Vaccine Nos","enrollment":63},{"nctId":"NCT01236066","phase":"","title":"Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Rotavirus Gastroenteritis, Gastroenteritis","enrollment":1},{"nctId":"NCT00289172","phase":"PHASE3","title":"Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-10","conditions":"Infections, Rotavirus","enrollment":360},{"nctId":"NCT00655187","phase":"","title":"Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04","conditions":"Rotavirus Severe Gastroenteritis","enrollment":1270},{"nctId":"NCT01086436","phase":"PHASE1","title":"Study to Evaluate the Safety of Rotarix™ in Chinese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-13","conditions":"Infections, Rotavirus","enrollment":50},{"nctId":"NCT01162590","phase":"PHASE1","title":"Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-01","conditions":"Infections, Rotavirus","enrollment":52},{"nctId":"NCT01107587","phase":"PHASE1","title":"Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-13","conditions":"Infections, Rotavirus","enrollment":50},{"nctId":"NCT01511133","phase":"","title":"Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Rotavirus Infection, Evidence of PCV-1 Replication and/or Immune Response to the PCV-1 in HRV Vaccinated Infants","enrollment":1},{"nctId":"NCT02252029","phase":"","title":"Rotavirus Vaccine in Premature Babies","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-12","conditions":"Gastroenteritis","enrollment":20},{"nctId":"NCT01960725","phase":"PHASE4","title":"An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)","status":"COMPLETED","sponsor":"Dennis Clements","startDate":"2014-02","conditions":"Diarrhea, Gastroenteritis","enrollment":66},{"nctId":"NCT00718237","phase":"PHASE3","title":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Rotavirus, Gastroenteritis","enrollment":762},{"nctId":"NCT00496054","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Gastroenteritis, Rotavirus","enrollment":110},{"nctId":"NCT00362648","phase":"PHASE3","title":"Developing World Study for RotaTeq™ (V260-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03","conditions":"Vomiting, Diarrhea, Fever","enrollment":7504},{"nctId":"NCT00140686","phase":"PHASE3","title":"To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-09","conditions":"Infections, Rotavirus","enrollment":3994},{"nctId":"NCT03031743","phase":"","title":"The Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-01","conditions":"Rotavirus","enrollment":88},{"nctId":"NCT01339221","phase":"","title":"Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Infections, Rotavirus","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[{"date":"2024 Dec 31","pmid":"38509699","title":"A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.","journal":"Human vaccines & immunotherapeutics"},{"date":"2012 May 22","pmid":"22568562","title":"Active site hydrophobic residues impact hydrogen tunneling differently in a thermophilic alcohol dehydrogenase at optimal versus nonoptimal temperatures.","journal":"Biochemistry"},{"date":"2011 Dec","pmid":"22129396","title":"Polymorphism in the acetylcholinesterase gene of Musca domestica L. field populations in Turkey.","journal":"Journal of vector ecology : journal of the Society for Vector Ecology"},{"date":"2010 Nov","pmid":"21225019","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"},{"date":"2008 Jun","pmid":"18806898","title":"Gateways to clinical trials.","journal":"Methods and findings in experimental and clinical pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"V260","genericName":"V260","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V260 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}